Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
120459472 | 12045947 | 2 | F | 20150112 | 20160713 | 20160208 | 20160719 | EXP | PHHY2016DE016783 | NOVARTIS | 0.00 | A | M | Y | 0.00000 | 20160719 | MD | DE | DE |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
120459472 | 12045947 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 2 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 3 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 4 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 5 | SS | TASIGNA | NILOTINIB | 1 | Oral | 300 MG, QD | 11400 | MG | U | 22068 | 300 | MG | QD | ||||
120459472 | 12045947 | 6 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 7 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 8 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD | ||||
120459472 | 12045947 | 9 | SS | TASIGNA | NILOTINIB | 1 | Oral | 300 MG, QD | 11400 | MG | U | 22068 | 300 | MG | QD | ||||
120459472 | 12045947 | 10 | SS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 11400 | MG | U | 22068 | 600 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
120459472 | 12045947 | 1 | Chronic myeloid leukaemia |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
120459472 | 12045947 | Chronic obstructive pulmonary disease | |
120459472 | 12045947 | Diarrhoea | |
120459472 | 12045947 | Syncope |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
120459472 | 12045947 | 1 | 20140325 | 0 | ||
120459472 | 12045947 | 2 | 20140514 | 0 | ||
120459472 | 12045947 | 3 | 20140709 | 0 | ||
120459472 | 12045947 | 4 | 20140813 | 0 | ||
120459472 | 12045947 | 5 | 20140901 | 20141008 | 0 | |
120459472 | 12045947 | 6 | 20141216 | 0 | ||
120459472 | 12045947 | 7 | 20150526 | 0 | ||
120459472 | 12045947 | 8 | 20151102 | 0 | ||
120459472 | 12045947 | 9 | 20160222 | 20160229 | 0 | |
120459472 | 12045947 | 10 | 20160530 | 0 |